← Evidence map

ReviewCancers2026

A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence.

Timothy Pluard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence. | Socratic